荷兰医学博士开题报告范文 Research Project Proposal

荷兰医学博士开题报告范文 Research Project Proposal 

论文题目：Role of stromal cells in the progression of Inflammatory Bowel Disease

论文语言：英语 English

论文专业：医学

字数：2000-3000

学校国家：荷兰

是否有数据处理要求：否

您的学校：XXX大学 排名89

论文用于：Doctor Application 博士申请

截止日期：2021-01-09

补充要求和说明： 申请留学的RP，有摘要，论文参考格式不清楚

The Role of Stromal Cells in the Progression of Inflammatory Bowel Disease

Research Project Proposal

Name of the PhD Candidate:     XXXX

Name of the Local Supervisor:   Prof. dr. XXX

Dr. L. XXX

Dr. A. XXX

Date of Submission:                   19-01-2021

Table of Contents

Introduction 3

Background and Problem Statement 3

Purpose of the Study 4

A Preliminary Review of Literature 4

Introductions 4

Functions in the Gut 6

Stromal cells in IBD progression 6

Stromal cell subsets in IBD progression 6

Stromal Cells and Immune Regulation 8

Research Questions 9

Research Design, Methods and Procedures 10

Ethical Considerations 10

Institutional Framework 11

Time Table of the proposed PhD Project 11

Expected Research Budgeting 12

Expected Limitations 12

Significance of the Study 12

References 14

Introduction

Inflammatory Bowel Diseases (IBD), which comprise Crohn’s disease (CD) and ulcerative colitis (UC) are chronic and relapsing inflammatory diseases of unknown etiology (ref). The epidemiology of IBD is widely studied and internationally, the cases are approximately 0.5 to 24.5 for every 100,000 cases for ulcerative colitis and 0.1 to 16 cases for every 100,000 people with the Crohn disease (Ha & Khalil, 2015). Many of these patients either require medication or surgery or are often hospitalized with Click et al., (2015) noting that up to 80% of Crohn’s victims shall be hospitalized at some point in their disease ecosystem with a majority of others having either prolonged or active remission. In the United States, circa 1-2 million individuals have Crohn or ulcerative colitis (Kappelman et al., 2007). The incidence of both diseases in the US is estimated to be 75-150 cases per 100 000 people (Rowe, 2020). In Europe, epidemiological data by 2013 suggested that 2.5-3 million people were affected by IBD with a high economic burden on healthcare, a cost circa 4.6-5.6 Euros/year (Burisch et al., 2013). Internationally, the highest incidences of IBD are seen in developed countries as compared to developing countries. The pathogenesis of this condition including the UC and CD entail a variety of pathogenic elements such as the abnormal gut microbiota, environmental changes, immune response dysregulations as well as the variants within the genes (Lee, Eun & Cho, 2018). Treatment has always been to treat the inflammation directly using immunosuppressive medication and to prevent the flares. When anti-inflammatory drugs are insufficient, surgery is the only remaining option in these severe cases. 

Background and Problem Statement

 For a long time, treatment of IBD has focused on symptomatic and supportive care, focusing on targeting the inflammatory cells directly. Very recently evidence, however, has suggested a role of stromal cells (non-epithelial cells/fibroblast) in IBD progression (Kinchen et al., 2018). However very little is known of the role they play in disease progression, how they functionally interact with infiltrating immune cells, and how they affect/are affected by current therapies. Therefore, this research project focuses on the role of the stromal cells in the progression of IBD and response to current IBD medication. This knowledge is relevant both in the quest for new therapeutic options for IBD, assess parameters predicting he effectiveness of current IBD medication and i